Onartuzumab for Gastroesophageal Adenocarcinoma
Manish A Shah, MD, talks about a recent phase II study of FOLFOX with or without onartuzumab, a MET inhibitor, for the treatment of metastatic gastroesophageal adenocarcinoma.
Manish A Shah, MD, director of gastrointestinal oncology at Weill Cornell Medical College/New York Presbyterian Hospital, talks about a recent phase II study of FOLFOX with or without onartuzumab, a MET inhibitor, for the treatment of metastatic gastroesophageal adenocarcinoma (GEC).
Clinical Pearls:
- The MET pathway is often overexpressed in gastric cancer. If there is a MET amplification in addition to the overexpression, the cancer can be more aggressive.
- The study found that the addition of onartuzumab to FOLFOX did not improve progression-free survival or overall survival in either an unselected population or in MET-positive patients.
- More research is needed to identify patients that benefit from MET inhibition
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
Oncologists Discuss a Second-Generation BTK for Relapsed/Refractory CLL
December 18th 2024During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed chronic lymphocytic leukemia after receiving venetoclax and obinutuzumab.
Read More
